Insmed Inc (NASDAQ:INSM) saw a downside of -0.65% to close Friday at $26.17 after subtracting -$0.17 on the day. The 5-day average trading volume is 991,100 shares of the company’s common stock. It has gained $26.80 in the past week and touched a new high 1 time within the past 5 days. An average of 1,741,575 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,404,850.
INSM’s 1-month performance is 18.47% or $4.52 on its low of $21.21 reached on 08/29/23. The company’s shares have touched a 52-week low of $16.04 and high of $27.59, with the stock’s rally to the 52-week high happening on 09/12/23. YTD, INSM has achieved 30.98% or $6.19 and has reached a new high 12 times. However, the current price is down -5.15% from the 52-week high price.
Insider Transactions
INSM stock investors last saw insider trading activity on Jul 11.Smith Michael Alexander (General Counsel, Senior VP) most recently sold 740 shares at $20.18 per share on Jul 11. This transaction cost the insider $14,933. Chief Operating Officer, Adsett Roger, sold 8,981 shares at a price of $19.32 on Jun 13. Then, on Jun 13, Chief Medical Officer Flammer Martina M.D. sold 8,868 shares at a price of $19.27 per share. This transaction amounted to $170,886.
Valuation Metrics
INSM stock has a beta of 1.48. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 13.97.
Insmed Inc’s quick ratio for the period ended June 29 was 4.77, with the current ratio over the same period at 5.15. In terms of profitability, the gross margin trailing 12 months is 76.99%. The firm’s gross profit as reported stood at $190.23 million against revenue of $245.36 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 60.93% to -$244.81 million, while revenue of -$159.76 million was 34.74% off the previous quarter. Analysts expected INSM to announce -$1.13 per share in earnings in its latest quarter, but it posted -$1.78, representing a -57.50% surprise. EBITDA for the quarter stood at more than -$230.27 million. INSM stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 1.59 billion, with total debt at $1.34 billion. Shareholders hold equity totaling $143.8 million.
Let’s look briefly at Insmed Inc (INSM) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 September was 59.57% to suggest the stock is trending Neutral, with historical volatility in this time period at 29.26%.
The stock’s 5-day moving average is $26.18, reflecting a -1.65% or -$0.44 change from its current price. INSM is currently trading +19.33% above its 20-day SMA, +29.75% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +24.80% and SMA200 by+31.57%.
Stochastic %K and %D was 67.34% and 72.02% and the average true range (ATR) pointed at 0.89. The RSI (14) points at 62.59%, while the 14-day stochastic is at 60.50% with the period’s ATR at 0.88. The stock’s 9-day MACD Oscillator is pointing at -0.37 and -0.39 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Insmed Inc (NASDAQ: INSM), Guggenheim launched coverage with a Buy rating. Analysts offering their rating for INSM stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate INSM as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 11 have offered a “buy” rating.
What is INSM’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $33.00 and a high of $54.00, with their median price target at $41.50. Looking at these predictions, the average price target given by analysts is for Insmed Inc (INSM) stock is $42.58.
